This is the part that SI and the rest of the group will highlight and focus on, in the upcoming conference call:-
“Under the RMAT designation, Mesoblast received specific guidance from the FDA that reduction in major GI bleeding episodes and related hospitalizations in the current trial is a clinically meaningful outcome with a high unmet need that could meet requirements for an approvable regulatory endpoint.
In contrast, the FDA advised that the primary endpoint in the current trial of temporary weaning from full LVAD support is considered a biomarker and is not a clinically meaningful outcome in and of itself”
This is an overreaction by a market that clearly requires further clarification and guidance.
- Forums
- ASX - By Stock
- MSB
- Ann: LVAD Trial Results Provide Potential Regulatory Pathway
Ann: LVAD Trial Results Provide Potential Regulatory Pathway, page-56
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 274051 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 0.985 |
3 | 116426 | 0.980 |
2 | 84419 | 0.975 |
3 | 54211 | 0.970 |
5 | 98141 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
1.000 | 274051 | 2 |
1.005 | 49212 | 4 |
1.010 | 31212 | 2 |
1.015 | 72652 | 4 |
1.020 | 560 | 1 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |